Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME: Take the course for this article:
 Volume 59, Number 5, September 10, 2002
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Related articles in Neurology
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Patten, S. B.
Right arrow Articles by Metz, L. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Patten, S. B.
Right arrow Articles by Metz, L. M.
Related Collections
Right arrow Depression
Right arrow All Clinical trials
Right arrow Multiple sclerosis

Neurology 2002;59:744-746
© 2002 American Academy of Neurology
Brief Communications

Interferon ß1a and depression in secondary progressive MS: Data from the SPECTRIMS Trial

Scott B. Patten, MD, FRCP(C), PhD and Luanne M. Metz, MD, FRCP(C) for the SPECTRIMS Study Group*

From the Departments of Community Health Sciences and Psychiatry (Dr. Patten) and Clinical Neurosciences (Dr. Metz), University of Calgary, Alberta, Canada.

Address correspondence and reprint requests to Dr. S.B. Patten, University of Calgary, 3330 Hospital Drive NW, Calgary, Alberta, Canada T2N 4N1; e-mail: patten{at}ucalgary.ca

Depression is a suspected side effect of treatment with interferon ß1a in MS. However, an association with depression has not been confirmed by rigorous studies. During the SPECTRIMS clinical trial of interferon ß1a (Rebif) in secondary progressive MS, depression ratings were obtained from 365 subjects treated either with interferon ß1a or with placebo. No significant differences between groups emerged during 36 months of follow-up. These data suggest that depression is not a side effect of interferon ß1a.


Related articles in Neurology:

Depression is a treatable cause of suffering among multiple sclerosis patients and can result in suicide
Dennis Bourdette
Neurology 2002 59: 6-7. [Full Text]  



This article has been cited by other articles:


Home page
 Mult SclerHome page
S. Patten, J. Williams, and L. Metz
Anti-depressant use in association with interferon and glatiramer acetate treatment in multiple sclerosis
Multiple Sclerosis, April 1, 2008; 14(3): 406 - 411.
[Abstract] [PDF]

Home page
 Mult SclerHome page
J Porcel, J Rio, A Sanchez-Betancourt, M J Arevalo, M Tintore, N Tellez, C Borras, C Nos, and X Montalban
Long-term emotional state of multiple sclerosis patients treated with interferon beta
Multiple Sclerosis, November 1, 2006; 12(6): 802 - 807.
[Abstract] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
P A Arnett and J J Randolph
Longitudinal course of depression symptoms in multiple sclerosis
J. Neurol. Neurosurg. Psychiatry, May 1, 2006; 77(5): 606 - 610.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
Goldman Consensus Group
The Goldman Consensus statement on depression in multiple sclerosis
Multiple Sclerosis, June 1, 2005; 11(3): 328 - 337.
[Abstract] [PDF]

Home page
 PsychosomaticsHome page
R. Pandya, L. Metz, and S. B. Patten
Predictive Value of the CES-D in Detecting Depression Among Candidates for Disease-Modifying Multiple Sclerosis Treatment
Psychosomatics, April 1, 2005; 46(2): 131 - 134.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
S. B Patten, G. Francis, L. M Metz, M. Lopez-Bresnahan, P. Chang, and F. Curtin
The relationship between depression and interferon beta-1a therapy in patients with multiple sclerosis
Multiple Sclerosis, April 1, 2005; 11(2): 175 - 181.
[Abstract] [PDF]

Home page
 NeurologyHome page
R. M. Williams, A. P. Turner, M. Hatzakis Jr., J. D. Bowen, A. A. Rodriquez, and J. K. Haselkorn
Prevalence and correlates of depression among veterans with multiple sclerosis
Neurology, January 11, 2005; 64(1): 75 - 80.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
A. A. Asghar-Ali, K. H. Taber, R. A. Hurley, and L. A. Hayman
Pure Neuropsychiatric Presentation of Multiple Sclerosis
Am J Psychiatry, February 1, 2004; 161(2): 226 - 231.
[Full Text] [PDF]

Home page
 NeurologyHome page
S. B. Patten, C. A. Beck, J. V.A. Williams, C. Barbui, and L. M. Metz
Major depression in multiple sclerosis: A population-based perspective
Neurology, December 9, 2003; 61(11): 1524 - 1527.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
S Di Legge, M C Piattella, C Pozzilli, P Pantano, F Caramia, I F Pestalozza, A Paolillo, and G L Lenzi
Longitudinal evaluation of depression and anxiety in patients with clinically isolated syndrome at high risk of developing early multiple sclerosis
Multiple Sclerosis, June 1, 2003; 9(3): 302 - 306.
[Abstract] [PDF]

Home page
 JWatch PsychiatryHome page
Suicidal Intent and Depression in MS Patients
Journal Watch Psychiatry, November 6, 2002; 2002(1106): 3 - 3.
[Full Text]

Home page
 NeurologyHome page
E. D. Caine and S. R. Schwid
Multiple sclerosis, depression, and the risk of suicide
Neurology, September 10, 2002; 59(5): 662 - 663.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by AAN Enterprises, Inc.